Omni/Ultra trial
Not Applicable
Not yet recruiting
- Conditions
- Tuberculosis
- Registration Number
- PACTR201704002117402
- Lead Sponsor
- Ifakara Health Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 1600
Inclusion Criteria
Adult 18 years old and above presumptive TB patients
Ability to produce sputum
Exclusion Criteria
Presumptive TB patients with symptoms only attributable to extra-pulmonary TB
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Xpert® MTB/RIF Ultra utilize for tuberculosis detection in Tanzania?
How does the GeneXpert®Omni system compare to traditional sputum smear microscopy for TB diagnosis?
Are there specific biomarkers that enhance the accuracy of rifampicin resistance detection in this trial?
What adverse events are associated with Xpert® MTB/RIF Ultra implementation in primary healthcare settings?
How do Cepheid's technologies compare to other TB diagnostic tools like LPA or culture methods in sub-Saharan Africa?